疫苗ETF（159643）涨超3.7%，行业前景引发关注

Group 1 - The core viewpoint of the article highlights that the Chinese pharmaceutical industry is at the starting point of a global value reassessment, as emphasized during the JPM conference [1] - The domestic CXO industry is transitioning from a "cost advantage" model to a dual-driven approach of "technology + scale," leveraging capabilities in areas such as ADC, dual antibodies, and GLP-1 to evolve from "intermediate suppliers" to "global innovation enablers" [1] - There is a noticeable acceleration in the globalization of domestic pharmaceutical companies, with key trends including the iteration of technology platforms like ADC, multi-antibodies, and small nucleic acids, as well as significant transactions exceeding $10 billion with multinational corporations (MNCs) [1] Group 2 - The year 2026 is identified as a critical milestone for domestic pharmaceutical companies, marking a period of intensive verification of transformation effectiveness, with many companies initiating global registration studies, key data readouts, and new product applications [1] - The vaccine ETF (159643) tracks the vaccine biotechnology index (980015), which focuses on bioproducts, vaccine research and development, and related services, reflecting the overall performance of listed companies engaged in vaccine production, research, and sales [1]